Valneva Stock: Shares Hit Resistance Following 2025 Revenue Announcement

Preliminary 2025 Results Revealed

Valneva disclosed its preliminary results for fiscal year 2025 yesterday, reporting revenue of 174.7 million euros, consistent with the previous year's levels. The company also communicated an enhancement in its cash position, a critical element for a business in the advanced stage of clinical development. Attention is now turning to 2026, a year the laboratory has described as decisive. The initial Phase 3 results of its Lyme disease vaccine candidate, developed in partnership with Pfizer, are expected in the coming months. This program is the main potential growth driver for the group. The publication of the complete annual results is scheduled for March 16, followed by the first quarter results on May 7.

Technical Analysis of Valneva's Stock Price

From a technical standpoint, Valneva's stock price is precisely at its resistance level of 4.63 euros, which also corresponds to the upper Bollinger band at 4.66 euros. This technical confluence suggests that the stock is trading in the upper part of its recent channel, after having risen nearly 27% over a year. The Relative Strength Index (RSI), which measures the speed and magnitude of price movements, stands at 73, above the threshold of 70 generally considered as indicating an overbought zone. This reading reflects the intensity of the stock's recent upward movement. Concurrently, the price is significantly above its 50-day and 200-day moving averages, positioned at 4.03 and 3.67 euros respectively, confirming a well-established upward trend in the medium term. Whether or not the current resistance is breached will be a technical indicator to watch in the upcoming sessions.